59 related articles for article (PubMed ID: 24583857)
1. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
[TBL] [Abstract][Full Text] [Related]
3. A useful EGFR-TK ligand for tumor diagnosis with SPECT: development of radioiodinated 6-(3-morpholinopropoxy)-7-ethoxy-4-(3'-iodophenoxy)quinazoline.
Hirata M; Kanai Y; Naka S; Yoshimoto M; Kagawa S; Matsumuro K; Katsuma H; Yamaguchi H; Magata Y; Ohmomo Y
Ann Nucl Med; 2013 Jun; 27(5):431-43. PubMed ID: 23494210
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
Zhang B; Jiao J; Liu Y; Guo LX; Zhou B; Li GQ; Yao ZJ; Zhou GB
PLoS One; 2012; 7(11):e48748. PubMed ID: 23185274
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
Han SY; Ding HR; Zhao W; Teng F; Li PP
BMC Complement Altern Med; 2014 May; 14():165. PubMed ID: 24884778
[TBL] [Abstract][Full Text] [Related]
6. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
Huang HN; Hung PF; Chen YP; Lee CH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Non-Covalent Imidazo[1,2-
Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
[TBL] [Abstract][Full Text] [Related]
8. 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Postiglione I; Chiaviello A; Aloj SM; Palumbo G
Cell Prolif; 2013 Aug; 46(4):382-95. PubMed ID: 23869760
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
Douillard JY; Ostoros G; Cobo M; Ciuleanu T; Cole R; McWalter G; Walker J; Dearden S; Webster A; Milenkova T; McCormack R
J Thorac Oncol; 2014 Sep; 9(9):1345-53. PubMed ID: 25122430
[TBL] [Abstract][Full Text] [Related]
10. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Chmielecki J; Foo J; Oxnard GR; Hutchinson K; Ohashi K; Somwar R; Wang L; Amato KR; Arcila M; Sos ML; Socci ND; Viale A; de Stanchina E; Ginsberg MS; Thomas RK; Kris MG; Inoue A; Ladanyi M; Miller VA; Michor F; Pao W
Sci Transl Med; 2011 Jul; 3(90):90ra59. PubMed ID: 21734175
[TBL] [Abstract][Full Text] [Related]
11. Localization of
Shigeto H; Miyata H; Ashizawa T; Iizuka A; Kikuchi Y; Hozumi C; Maeda C; Yamaguchi K; Yamamura S; Akiyama Y
Cancer Genomics Proteomics; 2023; 20(4):375-382. PubMed ID: 37400147
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations.
Ahmadi A; Mohammadnejadi E; Razzaghi-Asl N
Comput Biol Med; 2023 Sep; 163():107204. PubMed ID: 37421739
[TBL] [Abstract][Full Text] [Related]
13. ZYZ384 suppresses the growth of EGFR-mutant non-small cell lung cancer by activating JNK/MAPK signaling pathway.
Nie XW; Nasim AA; Yao XJ; Fan XX
Chem Biol Drug Des; 2024 Jan; 103(1):e14408. PubMed ID: 38009559
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
[TBL] [Abstract][Full Text] [Related]
15. Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
Amrhein JA; Beyett TS; Feng WW; Krämer A; Weckesser J; Schaeffner IK; Rana JK; Jänne PA; Eck MJ; Knapp S; Hanke T
J Med Chem; 2022 Dec; 65(23):15679-15697. PubMed ID: 36384036
[TBL] [Abstract][Full Text] [Related]
16. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Mohammadnejadi E; Razzaghi-Asl N
J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors.
He P; Du L; Dai Q; Li G; Yu B; Chang L
Bioorg Chem; 2024 Jan; 142():106970. PubMed ID: 37984101
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
Björkelund H; Gedda L; Barta P; Malmqvist M; Andersson K
PLoS One; 2011; 6(9):e24739. PubMed ID: 21931838
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment.
Song D; Ding T; Zhai W; Shao L; Guo N; Jiang L; Zhang W; Zhao F; Wang J; Wang J; Ma J; Yan L
Analyst; 2023 Dec; 148(24):6325-6333. PubMed ID: 37947047
[TBL] [Abstract][Full Text] [Related]
20. Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
Björkelund H; Gedda L; Andersson K
PLoS One; 2011 Jan; 6(1):e16536. PubMed ID: 21304974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
